North Bethesda, Md. – September 24, 2026 -- The International Society for Pharmaceutical Engineering (ISPE) will convene its 2026 Annual Meeting & Expo in Washington, D.C. from October 18-21, drawing pharmaceutical manufacturing leaders for four days of hybrid sessions combining in-person and virtual attendance.

Pune, India – September 22, 2026 -- The global lupus nephritis market was valued at $1.96 billion in 2025 and is projected to reach $4.08 billion by 2034, expanding at a compound annual growth rate of 8.5% through the forecast period, according to a new analysis by Maximize Market Research.

Holon, Israel – September 22, 2026 -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) will host a virtual key opinion leader event on October 5, 2026 at 8:00 AM ET, presenting new detail on COM701, its anti-PVRIG antibody candidate for relapsed platinum-sensitive ovarian cancer (PSOC).

Shanghai – September 09, 2026 -- Harbour BioMed (HKEX: 02142.HK) shares became eligible for trading under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, opening direct access for qualified mainland Chinese investors effective immediately.

Market capitalization crosses HK$10 billion threshold

The inclusion follows the Company's market capitalization steadily surpassing HK$10 billion, placing it among large- and mid-cap biopharmaceutical issuers on the Hong Kong exchange.

SOUTH SAN FRANCISCO, Calif. -- September 01, 2026 -- IDEAYA Biosciences said its FDA Type C meeting on IDE849, a DLL3-targeting antibody drug conjugate, produced agreement on a Phase 3 registrational trial design for extensive stage small cell lung cancer (ES-SCLC). The Nasdaq-listed company (IDYA) plans to enroll roughly 400 patients who have already received tarlatamab, randomizing them 1:1 between IDE849 monotherapy and an investigator's choice control arm of topotecan and amrubicin. IDEAYA is targeting trial initiation by year-end 2026.